Copenhagen, Denmark
Onsite/Online

ESTRO 2022

Session Item

Urology
Poster (digital)
Clinical
MR-guided adaptive versus CT-guided SBRT for prostate cancer: where is cost-benefit balance?
Alessandra Castelluccia, Italy
PO-1401

Abstract

MR-guided adaptive versus CT-guided SBRT for prostate cancer: where is cost-benefit balance?
Authors:

Alessandra Castelluccia1, Domenico Marchesano2, Gianmarco Grimaldi3, Ivan Annessi2, Federico Bianciardi2, Annamaria Di Palma2, Veronica Confaloni3, Federica Rea3, Barbara Tolu3, Maria Valentino2, Laura Verna2, Maria Rago2, Cristian Borrazzo2, Luca Capone3, Marica Masi2, Randa El Gawhary2, PierCarlo Gentile2,3

1San Pietro FBF, Radiantion Oncology, Rome, Italy; 2San Pietro FBF, Radiation Oncology, Rome, Italy; 3UPMC San Pietro FBF, Radiation Oncology, Rome, Italy

Show Affiliations
Purpose or Objective

The purpose of this study is to compare different techniques of SBRT for localized prostate cancer (PCa), stereotactic MR-guided adaptive RT (SMART) versus cone beam CT(CBCT)-guided SBRT, in terms of toxicity and time costs.

Material and Methods

Patient with localized PCa (clinical stage T1-2bN0M0) underwent SBRT using CT-LINAC system (True Beam STx, Varian) or MR-hybrid LINAC system (MRIdian, Viewray). SBRT was prescribed to a dose of 40 Gy (8 Gy/fr) and  36.75 Gy  (7.25 Gy/fr) to prostate and PTV, respectively, at 80% isodose, delivered on 5 days (3fr/week).  An anisotropic 5mm-margin (3mm posterior) was created around the prostate for the PTV. Treatment was delivered using two different image guidance (IG) strategies. CT-guided SBRT strategy consisted of a pre-treatment CBCT acquisition with  implanted fiducial markers and images matching using the ExacTrac® system. SMART consisted of indentification of target and OARs on pre-treatment MR images, with on-line calculation and delivery of a new plan for every fractions because of inter-fraction variation of bladder and rectal filling. Then an intra-fraction motion management strategy  was applied, consisting of a gating approach based on the real-time acquisition of a sagittal cine MRI during the whole delivery time (temporal resolution: 8 frames/s).   Mean time for each step of daily workflow was recorded. Common Terminology Criteria for Adverse Events was used to score gastrointestinal and genitourinary early toxicity during 3-month follow-up

Results

Sixty patients (pts) treated with prostate SBRT were compared. Real-time adaptive MR-guided RT strategy was used for 30 pts (50%) . Pre-treatment CBCT was performed in 150 treatments. Using CBCT-IG, grade 2 acute rectal toxicity occurred in 3 pts ; 1 pts with Grade 2  and 1 pts with grade 3 urinary toxicity were observed . No grade 2 and 3 toxicity was recorded for SMART treatments. Mean total daily treatment time was about 13 (range 11-17) and 24 (range 22-30) minutes for CT-guided SBRT and SMART respectively. Treatment workflows are shown in table 1 and table 2..

Conclusion

SBRT for prostate cancer is a safe and effective treatment. CT-guided SBRT  involves acceptable toxicity , however it needs additional equipment (ie. fiducials placement, ExacTrac® system ) to assure interfraction organ-motion control and delivery precision. SMART for prostate cancer confirms efficacy and can reduce toxicity: on-line adaptive and real-tracking improve precision and safety , with a slight difference in the time of daily treatment. Further studies to evaluate the optimal balance between clinical advantages of SMART technologies and additional cost in terms of time and complexity are needed.